Contrasting Ortho Clinical Diagnostics (OCDX) and Its Rivals

Ortho Clinical Diagnostics (NASDAQ: OCDX) is one of 36 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Ortho Clinical Diagnostics to related companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, risk and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Ortho Clinical Diagnostics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ortho Clinical Diagnostics 0 1 11 0 2.92
Ortho Clinical Diagnostics Competitors 179 664 1087 34 2.50

Ortho Clinical Diagnostics presently has a consensus price target of $24.55, suggesting a potential upside of 13.74%. As a group, “Diagnostic substances” companies have a potential upside of 0.42%. Given Ortho Clinical Diagnostics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Ortho Clinical Diagnostics is more favorable than its peers.

Insider and Institutional Ownership

52.9% of shares of all “Diagnostic substances” companies are owned by institutional investors. 7.5% of shares of all “Diagnostic substances” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


This table compares Ortho Clinical Diagnostics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ortho Clinical Diagnostics N/A N/A N/A
Ortho Clinical Diagnostics Competitors -3,099.44% -696.75% -183.84%

Earnings and Valuation

This table compares Ortho Clinical Diagnostics and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ortho Clinical Diagnostics $1.77 billion -$211.90 million 74.41
Ortho Clinical Diagnostics Competitors $405.90 million $35.95 million -56.34

Ortho Clinical Diagnostics has higher revenue, but lower earnings than its peers. Ortho Clinical Diagnostics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


Ortho Clinical Diagnostics beats its peers on 8 of the 12 factors compared.

About Ortho Clinical Diagnostics

Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.

Receive News & Ratings for Ortho Clinical Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ortho Clinical Diagnostics and related companies with's FREE daily email newsletter.